---
title: "89Bio (ETNB.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ETNB.US.md"
symbol: "ETNB.US"
name: "89Bio"
industry: "Biotechnology"
datetime: "2026-05-20T14:42:11.501Z"
locales:
  - [en](https://longbridge.com/en/quote/ETNB.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ETNB.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ETNB.US.md)
---

# 89Bio (ETNB.US)

## Company Overview

89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.13 | 389 | - | - | - |
| PB | 4.42 | 298 | 4.42 | 4.42 | 2.45 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 14.84 |
| Highest Target | 55.00 |
| Lowest Target | 14.50 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ETNB.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ETNB.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ETNB.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ETNB.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**